Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide.
Thermo Fisher Scientific Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$608.23|
|52 Week High||US$412.80|
|52 Week Low||US$614.13|
|1 Month Change||10.49%|
|3 Month Change||23.41%|
|1 Year Change||45.46%|
|3 Year Change||148.95%|
|5 Year Change||289.74%|
|Change since IPO||6,602.94%|
Recent News & Updates
|TMO||US Life Sciences||US Market|
Return vs Industry: TMO underperformed the US Life Sciences industry which returned 58.3% over the past year.
Return vs Market: TMO exceeded the US Market which returned 36.2% over the past year.
Stable Share Price: TMO is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: TMO's weekly volatility (3%) has been stable over the past year.
About the Company
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.
Thermo Fisher Scientific Fundamentals Summary
|TMO fundamental statistics|
Is TMO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TMO income statement (TTM)|
|Cost of Revenue||US$18.62b|
Last Reported Earnings
Jul 03, 2021
Next Earnings Date
|Earnings per share (EPS)||21.76|
|Net Profit Margin||22.47%|
How did TMO perform over the long term?See historical performance and comparison
0.2%Current Dividend Yield
Is Thermo Fisher Scientific undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: TMO ($608.23) is trading above our estimate of fair value ($390.86)
Significantly Below Fair Value: TMO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: TMO is good value based on its PE Ratio (27.8x) compared to the US Life Sciences industry average (52.2x).
PE vs Market: TMO is poor value based on its PE Ratio (27.8x) compared to the US market (17.7x).
Price to Earnings Growth Ratio
PEG Ratio: TMO is poor value based on its PEG Ratio (14.9x)
Price to Book Ratio
PB vs Industry: TMO is overvalued based on its PB Ratio (6.5x) compared to the US Life Sciences industry average (6.1x).
How is Thermo Fisher Scientific forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TMO's forecast earnings growth (1.9% per year) is below the savings rate (2%).
Earnings vs Market: TMO's earnings (1.9% per year) are forecast to grow slower than the US market (14.9% per year).
High Growth Earnings: TMO's earnings are forecast to grow, but not significantly.
Revenue vs Market: TMO's revenue (7.9% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: TMO's revenue (7.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TMO's Return on Equity is forecast to be high in 3 years time (29.7%)
How has Thermo Fisher Scientific performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TMO has high quality earnings.
Growing Profit Margin: TMO's current net profit margins (22.5%) are higher than last year (14.3%).
Past Earnings Growth Analysis
Earnings Trend: TMO's earnings have grown significantly by 29.6% per year over the past 5 years.
Accelerating Growth: TMO's earnings growth over the past year (127.2%) exceeds its 5-year average (29.6% per year).
Earnings vs Industry: TMO earnings growth over the past year (127.2%) exceeded the Life Sciences industry 56.9%.
Return on Equity
High ROE: TMO's Return on Equity (23.3%) is considered high.
How is Thermo Fisher Scientific's financial position?
Financial Position Analysis
Short Term Liabilities: TMO's short term assets ($19.3B) exceed its short term liabilities ($6.9B).
Long Term Liabilities: TMO's short term assets ($19.3B) do not cover its long term liabilities ($23.9B).
Debt to Equity History and Analysis
Debt Level: TMO's debt to equity ratio (51%) is considered high.
Reducing Debt: TMO's debt to equity ratio has reduced from 67% to 51% over the past 5 years.
Debt Coverage: TMO's debt is well covered by operating cash flow (54.6%).
Interest Coverage: TMO's interest payments on its debt are well covered by EBIT (22.8x coverage).
What is Thermo Fisher Scientific current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: TMO's dividend (0.17%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.35%).
High Dividend: TMO's dividend (0.17%) is low compared to the top 25% of dividend payers in the US market (3.63%).
Stability and Growth of Payments
Stable Dividend: TMO is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: TMO is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: TMO is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TMO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Marc Casper (53 yo)
Mr. Marc N. Casper has been the Chief Executive Officer and President of Thermo Fisher Scientific, Inc. since October 15, 2009 and also has been its Chairman of the Board of Directors since February 26, 20...
CEO Compensation Analysis
Compensation vs Market: Marc's total compensation ($USD26.39M) is above average for companies of similar size in the US market ($USD11.36M).
Compensation vs Earnings: Marc's compensation has increased by more than 20% in the past year.
Experienced Management: TMO's management team is considered experienced (3.7 years average tenure).
Experienced Board: TMO's board of directors are considered experienced (9.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TMO insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Thermo Fisher Scientific Inc.'s employee growth, exchange listings and data sources
- Name: Thermo Fisher Scientific Inc.
- Ticker: TMO
- Exchange: NYSE
- Founded: 1956
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$238.660b
- Shares outstanding: 393.42m
- Website: https://www.thermofisher.com
Number of Employees
- Thermo Fisher Scientific Inc.
- 168 Third Avenue
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 22:54|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.